Angel Adegbesan

Stay informed with Angel Adegbesan’s coverage and analysis for Fortune.

  • a researcher works in a labFinance

    One of the most shorted stocks on the market just leapt 99%, putting a ‘rib-crunching’ squeeze on bearish bettors

    By Angel Adegbesan, Carmen Reinicke, and others
  • Switzerland’s pharmaceutical group Roche CEO Severin Schwan talks during a meeting with journalists in Paris on September 19, 2016. / AFP PHOTO / ERIC PIERMONT (Photo credit should read ERIC PIERMONT/AFP via Getty Images)Health

    Why a biotech firm’s market value jumped from $3 million to $130 million in a day and is still way up from its ‘almost unfathomably low valuation’

    By Angel Adegbesan and Bloomberg
  • Jacksonville, FL – August 25: Ashley Dunham preps for her weekly dosage of Ozempic. (Malcom Jackson for The Washington Post via Getty Images)Health

    Weight-loss drugs like Ozempic are in such huge demand that spending on them will hit $100 billion by 2035, analyst says

    By Angel Adegbesan and Bloomberg
  • Lars Fruergaard Jorgensen, chief executive officer of Novo Nordisk, speaks during a Bloomberg Television interview in New York, US, on Wednesday, Aug. 10, 2022. Two more factories will begin producing Novo Nordisk A/S’s obesity medication Wegovy next year after manufacturing issues and high demand left the drug in short supply, Jorgensen said. Photographer: Christopher Goodney/Bloomberg via Getty ImagesHealth

    Weight-loss stocks soar up to 15% after obesity-drug study shows an added benefit that may be a ‘huge win’ for future sales

    By Angel Adegbesan, Jameelah Robinson, and others
  • NYSE traderFinance

    The A.I. mania is so red hot that a small $50 million investment from Nvidia sent an obscure biotech firm’s shares up a record 78%

    By Angel Adegbesan and Bloomberg